过去一年中添加的文章,按日期排序

… Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group …

S Kahraman, E Erul, O Gumusay, C Erol, T Sakalar… - papers.ssrn.com
2 天前 - difference was present between the palbociclib and ribociclib groups (p=0.70).
Real-world median overall survival … , there was a significant difference in mPFS between patients …

Artificial Intelligence-driven Prediction Revealed CFTR Associated With Therapy Outcome Of Breast Cancer: A Feasibility Study

M Kováčová, V Hlaváč, R Koževnikovová, K Rauš… - Oncology - pubmed.ncbi.nlm.nih.gov
2 天前 - … the functional consequences of genomic differences between individuals, many of
which … Methods: The study has been conducted on breast cancer patients of homogeneous …

Evaluation of the Clinical Efficacy of Ru'ai Shuhou Recipe for the Prevention of Lung Metastases from Breast Cancer: A Retrospective Study Based on Propensity …

N DU, S Shao, J Feng, X Wu, H Wan - Frontiers in Pharmacology - frontiersin.org
2 天前 - survival analysis and Cox survival analysis to explore the relationship between
RSR and 5-year disease-free survival and incidence of lung metastases in breastdifference

[HTML][HTML] Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first …

L Jia, J Peng, N Sun, H Chen, Z Liu, W Zhao, Q Zhang… - BMC cancer, 2024 - Springer
3 天前 - … -Meier survival curve was used to analyze the differences of … breast cancer and
previous first-line treatment of advanced breast cancer, but whether it can predict the survival

Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates

LV Selby, E Clark, JL Chen, G Tinoco… - Journal of Surgical … - Wiley Online Library
3 天前 - … Fisher's exact test, differences in survival were calculated using … of the breast
comprises less than 1% of all breast cancers, … These two patients were excluded from our survival

[HTML][HTML] Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

S Scagnoli, S Pisegna, A Toss, R Caputo… - … Breast Cancer, 2024 - nature.com
3 天前 - … in progression-free survival (PFS) and overall survival (OS) … outcomes, final overall
survival results for patients who … there was no significant difference among the other age-…

[HTML][HTML] The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer

WK Park, SJ Nam, SW Kim, JE Lee, J Yu, SK Lee… - Cancers, 2024 - mdpi.com
3 天前 - … experience better survival rates than HER2-0 TNBC. This difference was especially
survival in patients with HER2-low breast cancer compared to patients with HER2-0 …

Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer

JC Dalton, KA Crowell, KW Ntowe… - Annals of Surgical …, 2024 - Springer
4 天前 - differences in treatment and overall survival (OS) in older patients with HER2-positive
breast cancer … to assess the differences in treatment decisions and overall survival (OS) …

Should palpable nodes be exclusionary in patients who are otherwise candidates for ACOSOG Z0011-type trials?

CL Cardarelli, EC Dalton, C Chang… - Annals of Surgical …, 2024 - Springer
4 天前 - … A complete examination for breast cancer includes palpation … Axillary management
in breast cancer has evolved … This study observed no difference in survival with or …

The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis

Y Kong, J Huang, Y Ding, S Chen, Q Li… - Clinical and Translational …, 2024 - Springer
4 天前 - Objective The main goal of the present research is to explore the potential link of
body mass index (BMI) with different survival metrics in breast cancer patients. Our aim is to …